Sunday, April 30, 2017
   
Text Size

TB/HIV Unit


Bookmark and Share

TB/HIV UNIT

Senior Technical Adviser HIV/TB/DR-TB
Swaswata Dutt
MBBS, MS, FHM

 

BACKGROUND

The Institute provides treatment care and support for People Living with HIV/AIDS (PLHIV). This includes opportunistic infections management, most prominent of which is the tuberculosis infection. Tuberculosis is the leading cause of death among PLHIV in Sub Saharan Africa (Nigeria inclusive) and the most common opportunistic infection.

 

TB/HIV services :

IHVN provides TB/HIV services under both its ACTION Plus Up and Global Fund projects. This involves screening PLHIV for TB at every contact with health care workers, offering treatment to co-infected patients and providing PLHIV screened negative for active TB with preventive intervention.

IHVN supports the National TB and Leprosy Control Program (NTBLCP) through promoting the integration of HIV prevention, treatment and care to the support for TB care and treatment. The Institute has been active in the TB control through interventions such as:

  • Routine screening of all PLHIV at every contact with health care workers for TB.
  • HIV counseling and testing for clients at TB facilities.
  • Early diagnosis and treatment of PLHIV with active TB.
  • Ensuring that cross-referrals are made for TB patients to provide adequate care and treatment for HIV/AIDS, including antiretroviral treatment and cotrimoxazole preventive therapy and vice versa.
  • PLHIV screened negative for active TB disease are provided with Isoniazid Preventive Therapy.
  • Capacity development of Nigerian Health workers on TB/HIV integration.


STRATEGIES
: To achieve set goals, the Institute promotes capacity development through focused trainings centrally and regionally for trainees and also aims to generate a pool of trainers to ensure adequate capacity. The use of referral volunteers, coordinators and peer educators at sites as a strategy has helped to improve results. IHVN also promotes routine mentoring on good clinical practice based on evidence and best practices.


Achievements (from April 06 – December 16)

  1. PLHIV treated for TB…………………………….. 43,597
  2. Patients provided TB preventive therapy (IPT)……….... 8,556
  3. TB patients offered HIV Testing Services………… 196,055
  4. Sites practicing TB/HIV collaboration ……………… 160

Drug- Resistant TB Services :

The global threat of Drug Resistant TB (DR-TB) has great significance in the field of public health and is a reflection of weaknesses in drug-sensitive TB management. Early, accurate diagnosis and immediate, proper curative treatment, supported and supervised, taken for appropriate duration are essential elements to TB control. Nigeria ranks 13th among the 27 high burden DR-TB countries in the world. The estimates from the WHO Global Report (2016) revealed 4.3% of Rifampicin-Resistant/Multi-Drug Resistant (RR-TB/MDR-TB) among newly detected TB cases, and 25% among previously treated cases. IHVN is the Principal Recipient (PR) for drug-resistant TB for GF New Funding Model grant.

 

Achievements (From July 2011 to December 2016):

  • Number of presumptive DR-TB cases that receive testing for DR-TB (RR-TB and/or MDR-TB) in Nigeria………………………………………………………………. 149,569
  • Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified in Nigeria ………………………………………………………………………… 4,475
  • Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment in Nigeria……………………………………………………………… 2,834
  • Number of service providers trained on RR-TB/MDR -TB management in Nigeria…. 1,608
  • Percentage of DST (drug susceptibility testing) laboratories showing adequate performance on External Quality Assurance in Nigeria: 4 out of 5 = 80%

Other Events:

  • IHVN has also acquired GeneXpert MTB/RIF machines to ease the difficulties faced by clients in early diagnosis of TB in PLHIV and provide quality care to the clients.
  • IHVN provides maintenance to eight (8) TB Reference Laboratories and has supported the NTBLCP, through the GF DR-TB Grant, to activate 16 Drug Resistant TB (DR-TB) treatment centers within the country.

Unit contact email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

:: Privacy Policy

IHVN frowns at reproduction of the content of this website without prior permission.This act is illegal and punishable under the law.

:: Support and Funding

The Institute of Human Virology, Nigeria AITRP Training Programmes are supported and funded by the Fogarty International Center.
FacebookTwitterGoogleYoutube

IHVN Member's Logon